TG Therapeutics (TGTX) shares are in focus after the company secured a new five year US$750 million senior secured credit facility with Blue Owl Capital, refinancing US$250 million in existing debt ...
A TG Therapeutics multiple sclerosis drug that’s new to the U.S. market will be commercialized in Europe and other regions under a partnership that pays the biotech $140 million up front. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results